221 related articles for article (PubMed ID: 33208919)
41. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
42. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
[TBL] [Abstract][Full Text] [Related]
43. BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases.
Bachet JB; Moreno-Lopez N; Vigano L; Marchese U; Gelli M; Raoux L; Truant S; Laurent C; Herrero A; Le Roy B; Deguelte Lardiere S; Passot G; Hautefeuille V; De La Fouchardiere C; Artru P; Ameto T; Mabrut JY; Schwarz L; Rousseau B; Lepère C; Coriat R; Brouquet A; Sa Cunha A; Benoist S
Br J Surg; 2019 Aug; 106(9):1237-1247. PubMed ID: 31183866
[TBL] [Abstract][Full Text] [Related]
44. Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?
Passot G; Kim BJ; Glehen O; Mehran RJ; Kopetz SE; Goere D; Overman MJ; Pocard M; Marchal F; Conrad C; Aloia TA; Vauthey JN; Chun YS;
Ann Surg Oncol; 2018 Jan; 25(1):179-187. PubMed ID: 29071660
[TBL] [Abstract][Full Text] [Related]
45. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.
Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889
[TBL] [Abstract][Full Text] [Related]
46. Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer.
Christensen TD; Palshof JA; Larsen FO; Poulsen TS; Høgdall E; Pfeiffer P; Jensen BV; Yilmaz MK; Nielsen D
Acta Oncol; 2018 Aug; 57(8):1057-1062. PubMed ID: 29380640
[TBL] [Abstract][Full Text] [Related]
47. Prognostic Role of BRAF Mutations in Colorectal Cancer Liver Metastases.
Pikoulis E; Margonis GA; Andreatos N; Sasaki K; Angelou A; Polychronidis G; Pikouli A; Riza E; Pawlik TM; Antoniou E
Anticancer Res; 2016 Sep; 36(9):4805-11. PubMed ID: 27630332
[TBL] [Abstract][Full Text] [Related]
48. KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.
Shindoh J; Nishioka Y; Yoshioka R; Sugawara T; Sakamoto Y; Hasegawa K; Hashimoto M; Kokudo N
Ann Surg Oncol; 2016 Jun; 23(6):1890-6. PubMed ID: 26786089
[TBL] [Abstract][Full Text] [Related]
49. Introduction of the resection severity index as independent risk factor limiting survival after resection of colorectal liver metastases.
Gwiasda J; Schrem H; Kaltenborn A; Mahlmann J; Mix H; Lehner F; Kayser N; Klempnauer J; Kulik U
Surg Oncol; 2017 Dec; 26(4):382-388. PubMed ID: 29113656
[TBL] [Abstract][Full Text] [Related]
50. Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor.
Fujiyoshi K; Yamamoto G; Takenoya T; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
Anticancer Res; 2017 Jan; 37(1):239-247. PubMed ID: 28011498
[TBL] [Abstract][Full Text] [Related]
51. Prognostic impact of K-RAS mutational status and primary tumor location in patients undergoing resection for colorectal cancer liver metastases: an update.
O Connor JM; Sanchez Loria F; Ardiles V; Grondona J; Sanchez P; Andriani O; Fauda M; Brancato F; Huertas E; Alvarez F; de Santibañes E
Future Oncol; 2019 Sep; 15(27):3149-3157. PubMed ID: 31426677
[No Abstract] [Full Text] [Related]
52. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM
Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540
[TBL] [Abstract][Full Text] [Related]
53. MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases.
Isella C; Mellano A; Galimi F; Petti C; Capussotti L; De Simone M; Bertotti A; Medico E; Muratore A
Ann Surg; 2013 Jun; 257(6):1089-95. PubMed ID: 23665971
[TBL] [Abstract][Full Text] [Related]
54. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection.
Passot G; Denbo JW; Yamashita S; Kopetz SE; Chun YS; Maru D; Overman MJ; Brudvik KW; Conrad C; Aloia TA; Vauthey JN
Surgery; 2017 Feb; 161(2):332-340. PubMed ID: 27592215
[TBL] [Abstract][Full Text] [Related]
55. Prognostic assessment of resected colorectal liver metastases integrating pathological features, RAS mutation and Immunoscore.
Baldin P; Van den Eynde M; Mlecnik B; Bindea G; Beniuga G; Carrasco J; Haicheur N; Marliot F; Lafontaine L; Fredriksen T; Lanthier N; Hubert C; Navez B; Huyghe N; Pagès F; Jouret-Mourin A; Galon J; Komuta M
J Pathol Clin Res; 2021 Jan; 7(1):27-41. PubMed ID: 32902189
[TBL] [Abstract][Full Text] [Related]
56. Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.
Frankel TL; Vakiani E; Nathan H; DeMatteo RP; Kingham TP; Allen PJ; Jarnagin WR; Kemeny NE; Solit DB; D'Angelica MI
Cancer; 2017 Feb; 123(4):568-575. PubMed ID: 27737491
[TBL] [Abstract][Full Text] [Related]
57. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases.
Nash GM; Gimbel M; Shia J; Nathanson DR; Ndubuisi MI; Zeng ZS; Kemeny N; Paty PB
Ann Surg Oncol; 2010 Feb; 17(2):572-8. PubMed ID: 19727962
[TBL] [Abstract][Full Text] [Related]
58. Comprehensive Analysis of the Relationship Between RAS and RAF Mutations and MSI Status of Colorectal Cancer in Northeastern China.
Li W; Li H; Liu R; Yang X; Gao Y; Niu Y; Geng J; Xue Y; Jin X; You Q; Geng J; Meng H
Cell Physiol Biochem; 2018; 50(4):1496-1509. PubMed ID: 30359964
[TBL] [Abstract][Full Text] [Related]
59. [Epidemiological characteristics of early-onset colorectal cancer: a prospective cohort study from a single center].
Jin T; Zhu YS; Liu CC; Xu X; Lu W; Xiao Q; Ding KF; Zheng S
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 May; 27(5):457-463. PubMed ID: 38778685
[No Abstract] [Full Text] [Related]
60. Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors.
Bae JM; Cho NY; Kim TY; Kang GH
Dis Colon Rectum; 2012 Feb; 55(2):181-90. PubMed ID: 22228162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
